Research programme: dihydrocostatolide - National Cancer Institute/Sarawak MediChemAlternative Names: (-)-Dihydrocalanolide B; 7,8-Dihydrocostatolide; Dihydrocodstatolide; NSC 661123
Latest Information Update: 02 Mar 2009
At a glance
- Originator National Cancer Institute (USA)
- Class Antivirals; Coumarins; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV infections